| Product NDC: | 64980-175 |
| Proprietary Name: | CARISOPRODOL and ASPIRIN |
| Non Proprietary Name: | CARISOPRODOL and ASPIRIN |
| Active Ingredient(s): | 325; 200 mg/1; mg/1 & nbsp; CARISOPRODOL and ASPIRIN |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 64980-175 |
| Labeler Name: | Rising Pharmaceuticals, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA040832 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20100107 |
| Package NDC: | 64980-175-05 |
| Package Description: | 500 TABLET in 1 BOTTLE (64980-175-05) |
| NDC Code | 64980-175-05 |
| Proprietary Name | CARISOPRODOL and ASPIRIN |
| Package Description | 500 TABLET in 1 BOTTLE (64980-175-05) |
| Product NDC | 64980-175 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | CARISOPRODOL and ASPIRIN |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20100107 |
| Marketing Category Name | ANDA |
| Labeler Name | Rising Pharmaceuticals, Inc. |
| Substance Name | ASPIRIN; CARISOPRODOL |
| Strength Number | 325; 200 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Centrally-mediated Muscle Relaxation [PE],Muscle Relaxant [EPC],Cyclooxygenase Inhibitors [MoA],Decreased Prostaglandin Production [PE],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC] |